Literature DB >> 16391623

Intravitreal triamcinolone for treatment of complicated proliferative diabetic retinopathy and proliferative vitreoretinopathy.

Wuqaas M Munir1, Jose S Pulido, Mithlesh C Sharma, Bruce M Buerk.   

Abstract

BACKGROUND: We present a retrospective evaluation of the clinical outcome and complications associated with intravitreal injection of unaltered triamcinolone acetonide in conjunction with pars plana vitrectomy and silicone oil injection for the treatment of complicated proliferative diabetic retinopathy with tractional retinal detachment and severe proliferative vitreoretinopathy.
METHODS: Thirteen eyes of 12 consecutive patients were identified from a computerized patient database. All eyes were operated on by the same surgeon and received 4 mg of unaltered, commercially available triamcinolone acetonide intravitreally, before silicone oil injection. The patients were followed for a mean of 4.7 months (range 1-15 months), and demographic as well as pertinent preoperative and postoperative clinical information was gathered.
RESULTS: At the last follow-up visit, vision had improved in 4 eyes, remained stable in 5 eyes, and worsened in 4 eyes. The retina was attached at the end of follow-up in 10 of the 13 eyes. Eight of the 13 eyes did not show any clinical signs of re-roliferation or redetachment during the course of follow-up. The mean intra-ocular pressure did not increase (preoperative value was 10.8+/- 6.22 mm Hg with a range of 0-22 mm Hg; at last follow-up, mean pressure was 9.6 +/-3.86 mm Hg with a cumulative postoperative range of 0-26 mm Hg). Steroid crystals were visible at 1 month postoperatively in 3 eyes and did not hinder fundus examination significantly.
INTERPRETATION: The intravitreal injection of low-dose, unaltered triamcinolone acetonide in the setting of pars plana vitrectomy and silicone oil injection for the treatment of proliferative vitreoretinopathy and complicated proliferative diabetic retinopathy appears to be well tolerated. Further controlled study is needed to clearly define the potential beneficial effects of intravitreal steroids in these 2 disease processes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16391623     DOI: 10.1016/S0008-4182(05)80052-3

Source DB:  PubMed          Journal:  Can J Ophthalmol        ISSN: 0008-4182            Impact factor:   1.882


  14 in total

1.  Inhibition of neovascularization but not fibrosis with the fluocinolone acetonide implant in autosomal dominant neovascular inflammatory vitreoretinopathy.

Authors:  Paul S Tlucek; James C Folk; Jason A Orien; Edwin M Stone; Vinit B Mahajan
Journal:  Arch Ophthalmol       Date:  2012-11

Review 2.  A review of therapies for diabetic macular oedema and rationale for combination therapy.

Authors:  W M K Amoaku; S Saker; E A Stewart
Journal:  Eye (Lond)       Date:  2015-06-26       Impact factor: 3.775

3.  Intravitreal triamcinolone for intraocular inflammation and associated macular edema.

Authors:  Steven M Couch; Sophie J Bakri
Journal:  Clin Ophthalmol       Date:  2009-06-02

4.  Posterior subtenon triamcinolone acetonide in gas-filled eyes as an adjunctive treatment for complicated proliferative diabetic retinopathy.

Authors:  Yongeun Lee; Seungbum Kang; Young-Hoon Park
Journal:  Korean J Ophthalmol       Date:  2013-01-09

Review 5.  Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives.

Authors:  Sherif A Gaballa; Uday B Kompella; Omar Elgarhy; Ali M Alqahtani; Barbara Pierscionek; Raid G Alany; Hamdy Abdelkader
Journal:  Drug Deliv Transl Res       Date:  2021-06       Impact factor: 4.617

Review 6.  Pharmacotherapy as an adjunct to vitrectomy.

Authors:  Victor M Villegas; Mónica P González; Audina M Berrocal; Timothy G Murray
Journal:  Ther Adv Ophthalmol       Date:  2021-05-23

7.  BOL-303242-X, a novel selective glucocorticoid receptor agonist, with full anti-inflammatory properties in human ocular cells.

Authors:  Jin-Zhong Zhang; Megan E Cavet; Karl R VanderMeid; Mercedes Salvador-Silva; Francisco J López; Keith W Ward
Journal:  Mol Vis       Date:  2009-12-08       Impact factor: 2.367

8.  Surgical management of fibrotic encapsulation of the fluocinolone acetonide implant in CAPN5-associated proliferative vitreoretinopathy.

Authors:  Paul S Tlucek; James C Folk; Warren M Sobol; Vinit B Mahajan
Journal:  Clin Ophthalmol       Date:  2013-06-10

9.  A pilot study of intraocular use of intensive anti-inflammatory; triamcinolone acetonide to prevent proliferative vitreoretinopathy in eyes undergoing vitreoretinal surgery for open globe trauma; the Adjuncts in Ocular Trauma (AOT) Trial: study protocol for a randomised controlled trial.

Authors:  Philip J Banerjee; Malcolm G Woodcock; Catey Bunce; Robert Scott; David G Charteris
Journal:  Trials       Date:  2013-02-13       Impact factor: 2.279

10.  Ozurdex (a slow-release dexamethasone implant) in proliferative vitreoretinopathy: study protocol for a randomised controlled trial.

Authors:  Philip J Banerjee; Catey Bunce; David G Charteris
Journal:  Trials       Date:  2013-10-28       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.